{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:15:10Z","timestamp":1789604110446,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1038\/cgt.2014.54","type":"journal-article","created":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T11:16:31Z","timestamp":1415963791000},"page":"483-490","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Measles Edmonston vaccine strain derivatives have potent oncolytic activity against osteosarcoma"],"prefix":"10.1038","volume":"21","author":[{"given":"E","family":"Domingo-Musibay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J J","family":"Hardcastle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Aderca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Msaouel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T R","family":"DeGrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Galanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,14]]},"reference":[{"key":"BFcgt201454_CR1","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.4065\/82.11.1409","volume":"82","author":"KM Skubitz","year":"2007","unstructured":"Skubitz KM, D'Adamo DR . Sarcoma. Mayo Clin Proc 2007; 82: 1409\u20131432.","journal-title":"Mayo Clin Proc"},{"key":"BFcgt201454_CR2","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1056\/NEJM198606193142502","volume":"314","author":"MP Link","year":"1986","unstructured":"Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986; 314: 1600\u20131606.","journal-title":"N Engl J Med"},{"key":"BFcgt201454_CR3","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1200\/JCO.1997.15.1.76","volume":"15","author":"AJ Provisor","year":"1997","unstructured":"Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997; 15: 76\u201384.","journal-title":"J Clin Oncol"},{"issue":"Suppl 7","key":"BFcgt201454_CR4","doi-asserted-by":"crossref","first-page":"vii320","DOI":"10.1093\/annonc\/mdq276","volume":"21","author":"J Ritter","year":"2010","unstructured":"Ritter J, Bielack SS . Osteosarcoma. Ann Oncol 2010; 21 (Suppl 7): vii320\u2013vii325.","journal-title":"Ann Oncol"},{"key":"BFcgt201454_CR5","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1517\/14712598.2013.749851","volume":"13","author":"P Msaouel","year":"2013","unstructured":"Msaouel P, Opyrchal M, Domingo Musibay E, Galanis E . Oncolytic measles virus strains as novel anticancer agents. Expert Opin Biol Ther 2013; 13: 483\u2013502.","journal-title":"Expert Opin Biol Ther"},{"key":"BFcgt201454_CR6","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(71)92086-1","volume":"2","author":"AZ Bluming","year":"1971","unstructured":"Bluming AZ, Ziegler JL . Regression of Burkitt's lymphoma in association with measles infection. Lancet 1971; 2: 105\u2013106.","journal-title":"Lancet"},{"key":"BFcgt201454_CR7","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/S0140-6736(81)92286-8","volume":"1","author":"AM Taqi","year":"1981","unstructured":"Taqi AM, Abdurrahman MB, Yakubu AM, Fleming AF . Regression of Hodgkin's disease after measles. Lancet 1981; 1: 1112.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"BFcgt201454_CR8","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1093\/infdis\/170.Supplement_1.S32","volume":"170","author":"FT Cutts","year":"1994","unstructured":"Cutts FT, Markowitz LE . Successes and failures in measles control. J Infect Dis 1994; 170 (Suppl 1): S32\u2013S41.","journal-title":"J Infect Dis"},{"key":"BFcgt201454_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1517\/14712598.8.2.213","volume":"8","author":"C Allen","year":"2008","unstructured":"Allen C, Paraskevakou G, Liu C, Iankov ID, Msaouel P, Zollman P et al. Oncolytic measles virus strains in the treatment of gliomas. Expert Opin Biol Ther 2008; 8: 213\u2013220.","journal-title":"Expert Opin Biol Ther"},{"key":"BFcgt201454_CR10","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1158\/0008-5472.CAN-09-2762","volume":"70","author":"E Galanis","year":"2010","unstructured":"Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 2010; 70: 875\u2013882.","journal-title":"Cancer Res"},{"key":"BFcgt201454_CR11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s10549-009-0602-z","volume":"122","author":"ID Iankov","year":"2010","unstructured":"Iankov ID, Msaouel P, Allen C, Federspiel MJ, Bulur PA, Dietz AB et al. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast Cancer Res Treat 2010; 122: 745\u2013754.","journal-title":"Breast Cancer Res Treat"},{"key":"BFcgt201454_CR12","doi-asserted-by":"publisher","first-page":"7155","DOI":"10.1158\/1078-0432.CCR-07-1306","volume":"13","author":"C Liu","year":"2007","unstructured":"Liu C, Sarkaria JN, Petell CA, Paraskevakou G, Zollman PJ, Schroeder M et al. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Clin Cancer Res 2007; 13: 7155\u20137165.","journal-title":"Clin Cancer Res"},{"key":"BFcgt201454_CR13","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1089\/hum.2008.035","volume":"19","author":"R Myers","year":"2008","unstructured":"Myers R, Harvey M, Kaufmann TJ, Greiner SM, Krempski JW, Raffel C et al. Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I\/II clinical trial for patients with recurrent gliomas. Hum Gene Ther 2008; 19: 690\u2013698.","journal-title":"Hum Gene Ther"},{"key":"BFcgt201454_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/pros.20857","volume":"69","author":"M Pavlos","year":"2009","unstructured":"Pavlos M, Ianko DI, Cory A, John CM, Veronika von M, Roberto C et al. Engineered measles virus as a novel oncolytic therapy against prostate cancer. The Prostate 2009; 69: 82\u201391.","journal-title":"The Prostate"},{"key":"BFcgt201454_CR15","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.mayocp.2014.04.003","volume":"89","author":"SJ Russell","year":"2014","unstructured":"Russell SJ, Federspiel MJ, Peng KW, Tong C, Dingli D, Morice WG et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc 2014; 89: 926\u2013933.","journal-title":"Mayo Clin Proc"},{"key":"BFcgt201454_CR16","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1128\/jvi.67.10.6025-6032.1993","volume":"67","author":"D Naniche","year":"1993","unstructured":"Naniche D, Varior-Krishnan G, Cervoni F, Wild TF, Rossi B, Rabourdin-Combe C et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol 1993; 67: 6025\u20136032.","journal-title":"J Virol"},{"key":"BFcgt201454_CR17","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nature10639","volume":"480","author":"MD Muhlebach","year":"2011","unstructured":"Muhlebach MD, Mateo M, Sinn PL, Prufer S, Uhlig KM, Leonard VH et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 2011; 480: 530\u2013533.","journal-title":"Nature"},{"key":"BFcgt201454_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/0092-8674(93)80071-L","volume":"75","author":"RE Dorig","year":"1993","unstructured":"Dorig RE, Marcil A, Chopra A, Richardson CD . The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993; 75: 295\u2013305.","journal-title":"Cell"},{"key":"BFcgt201454_CR19","doi-asserted-by":"publisher","first-page":"9208","DOI":"10.1128\/JVI.01210-13","volume":"87","author":"M Mateo","year":"2013","unstructured":"Mateo M, Navaratnarajah CK, Syed S, Cattaneo R . The measles virus hemagglutinin beta-propeller head beta4-beta5 hydrophobic groove governs functional interactions with nectin-4 and CD46 but not with the signaling lymphocytic activation molecule. J Virol 2013; 87: 9208\u20139216.","journal-title":"J Virol"},{"key":"BFcgt201454_CR20","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S0161-5890(99)00115-7","volume":"36","author":"K Jurianz","year":"1999","unstructured":"Jurianz K, Ziegler S, Garcia-Schuler H, Kraus S, Bohana-Kashtan O, Fishelson Z et al. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 1999; 36: 929\u2013939.","journal-title":"Mol Immunol"},{"key":"BFcgt201454_CR21","first-page":"4943","volume":"26","author":"P Surowiak","year":"2006","unstructured":"Surowiak P, Materna V, Maciejczyk A, Kaplenko I, Spaczynski M, Dietel M et al. CD46 expression is indicative of shorter revival-free survival for ovarian cancer patients. Anticancer Res 2006; 26: 4943\u20134948.","journal-title":"Anticancer Res"},{"key":"BFcgt201454_CR22","doi-asserted-by":"publisher","first-page":"11840","DOI":"10.1158\/0008-5472.CAN-06-1200","volume":"66","author":"C Allen","year":"2006","unstructured":"Allen C, Vongpunsawad S, Nakamura T, James CD, Schroeder M, Cattaneo R et al. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res 2006; 66: 11840\u201311850.","journal-title":"Cancer Res"},{"key":"BFcgt201454_CR23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/0165-4608(94)90195-3","volume":"73","author":"MJ Bello","year":"1994","unstructured":"Bello MJ, de Campos JM, Kusak ME, Vaquero J, Sarasa JL, Pestana A et al. Molecular analysis of genomic abnormalities in human gliomas. Cancer Genet Cytogenet 1994; 73: 122\u2013129.","journal-title":"Cancer Genet Cytogenet"},{"key":"BFcgt201454_CR24","first-page":"4099","volume":"55","author":"C Linge","year":"1995","unstructured":"Linge C, Gewert D, Rossmann C, Bishop JA, Crowe JS . Interferon system defects in human malignant melanoma. Cancer Res 1995; 55: 4099\u20134104.","journal-title":"Cancer Res"},{"key":"BFcgt201454_CR25","doi-asserted-by":"publisher","first-page":"392","DOI":"10.7150\/thno.3722","volume":"2","author":"BC Ahn","year":"2012","unstructured":"Ahn BC . Sodium iodide symporter for nuclear molecular imaging and gene therapy: from bedside to bench and back. Theranostics 2012; 2: 392\u2013402.","journal-title":"Theranostics"},{"key":"BFcgt201454_CR26","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1182\/blood-2003-07-2233","volume":"103","author":"D Dingli","year":"2004","unstructured":"Dingli D, Peng KW, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004; 103: 1641\u20131646.","journal-title":"Blood"},{"key":"BFcgt201454_CR27","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/mt.2009.218","volume":"17","author":"P Msaouel","year":"2009","unstructured":"Msaouel P, Iankov ID, Allen C, Aderca I, Federspiel MJ, Tindall DJ et al. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther 2009; 17: 2041\u20132048.","journal-title":"Mol Ther"},{"key":"BFcgt201454_CR28","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00259-010-1523-0","volume":"37","author":"M Jauregui-Osoro","year":"2010","unstructured":"Jauregui-Osoro M, Sunassee K, Weeks AJ, Berry DJ, Paul RL, Cleij M et al. Synthesis and biological evaluation of [(18)F]tetrafluoroborate: a PET imaging agent for thyroid disease and reporter gene imaging of the sodium\/iodide symporter. Eur J Nucl Med Mol Imaging 2010; 37: 2108\u20132116.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"BFcgt201454_CR29","doi-asserted-by":"crossref","first-page":"9568","DOI":"10.1128\/JVI.73.11.9568-9575.1999","volume":"73","author":"WP Duprex","year":"1999","unstructured":"Duprex WP, McQuaid S, Hangartner L, Billeter MA, Rima BK . Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J Virol 1999; 73: 9568\u20139575.","journal-title":"J Virol"},{"key":"BFcgt201454_CR30","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/jor.21307","volume":"29","author":"T Kubo","year":"2011","unstructured":"Kubo T, Shimose S, Matsuo T, Fujimori J, Sakaguchi T, Yamaki M et al. Oncolytic vesicular stomatitis virus administered by isolated limb perfusion suppresses osteosarcoma growth. J Orthop Res 2011; 29: 795\u2013800.","journal-title":"J Orthop Res"},{"key":"BFcgt201454_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev.genet.32.1.123","volume":"32","author":"KK Conzelmann","year":"1998","unstructured":"Conzelmann KK . Nonsegmented negative-strand RNA viruses: genetics and manipulation of viral genomes. Annu Rev Genet 1998; 32: 123\u2013162.","journal-title":"Annu Rev Genet"},{"key":"BFcgt201454_CR32","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3892\/ijo.2012.1514","volume":"41","author":"S Atsumi","year":"2012","unstructured":"Atsumi S, Matsumine A, Toyoda H, Niimi R, Iino T, Nakamura T et al. Oncolytic virotherapy for human bone and soft tissue sarcomas using live attenuated poliovirus. Int J Oncol 2012; 41: 893\u2013902.","journal-title":"Int J Oncol"},{"key":"BFcgt201454_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2174\/156652312799789235","volume":"12","author":"AR Penheiter","year":"2012","unstructured":"Penheiter AR, Russell SJ, Carlson SK . The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies. Curr Gene Ther 2012; 12: 33\u201347.","journal-title":"Curr Gene Ther"},{"key":"BFcgt201454_CR34","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.bbrc.2009.08.062","volume":"388","author":"H Kumar","year":"2009","unstructured":"Kumar H, Kawai T, Akira S . Toll-like receptors and innate immunity. Biochem Biophys Res Commun 2009; 388: 621\u2013625.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFcgt201454_CR35","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nri2358","volume":"8","author":"M Gilliet","year":"2008","unstructured":"Gilliet M, Cao W, Liu YJ . Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008; 8: 594\u2013606.","journal-title":"Nat Rev Immunol"},{"key":"BFcgt201454_CR36","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1158\/1078-0432.CCR-12-2733","volume":"19","author":"JB Guillerme","year":"2013","unstructured":"Guillerme JB, Boisgerault N, Roulois D, Menager J, Combredet C, Tangy F et al. Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. Clin Cancer Res 2013; 19: 1147\u20131158.","journal-title":"Clin Cancer Res"},{"key":"BFcgt201454_CR37","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/sj.onc.1205179","volume":"21","author":"L Thyrell","year":"2002","unstructured":"Thyrell L, Erickson S, Zhivotovsky B, Pokrovskaja K, Sangfelt O, Castro J et al. Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene 2002; 21: 1251\u20131262.","journal-title":"Oncogene"},{"key":"BFcgt201454_CR38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1471-2407-12-93","volume":"12","author":"F Wimbauer","year":"2012","unstructured":"Wimbauer F, Yang C, Shogren KL, Zhang M, Goyal R, Riester SM et al. Regulation of interferon pathway in 2-methoxyestradiol-treated osteosarcoma cells. BMC Cancer 2012; 12: 93.","journal-title":"BMC Cancer"},{"key":"BFcgt201454_CR39","first-page":"6463","volume":"63","author":"D Grote","year":"2003","unstructured":"Grote D, Cattaneo R, Fielding AK . Neutrophils contribute to the measles virus-induced antitumor effect: enhancement by granulocyte macrophage colony-stimulating factor expression. Cancer Res 2003; 63: 6463\u20136468.","journal-title":"Cancer Res"},{"key":"BFcgt201454_CR40","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/cgt.2010.10","volume":"17","author":"H Li","year":"2010","unstructured":"Li H, Peng KW, Dingli D, Kratzke RA, Russell SJ . Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther 2010; 17: 550\u2013558.","journal-title":"Cancer Gene Ther"},{"key":"BFcgt201454_CR41","first-page":"52","volume":"10","author":"R Gupta","year":"2010","unstructured":"Gupta R, Emens LA . GM-CSF-secreting vaccines for solid tumors: moving forward. Discov Med 2010; 10: 52\u201360.","journal-title":"Discov Med"},{"key":"BFcgt201454_CR42","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ejca.2009.10.013","volume":"46","author":"S Bracarda","year":"2010","unstructured":"Bracarda S, Eggermont AM, Samuelsson J . Redefining the role of interferon in the treatment of malignant diseases. Eur J Cancer 2010; 46: 284\u2013297.","journal-title":"Eur J Cancer"},{"key":"BFcgt201454_CR43","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/mt.2012.4","volume":"20","author":"ID Iankov","year":"2012","unstructured":"Iankov ID, Allen C, Federspiel MJ, Myers RM, Peng KW, Ingle JN et al. Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus. Mol Ther 2012; 20: 1139\u20131147.","journal-title":"Mol Ther"},{"key":"BFcgt201454_CR44","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/sj.clpt.6100409","volume":"82","author":"RM Myers","year":"2007","unstructured":"Myers RM, Greiner SM, Harvey ME, Griesmann G, Kuffel MJ, Buhrow SA et al. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 2007; 82: 700\u2013710.","journal-title":"Clin Pharmacol Ther"},{"key":"BFcgt201454_CR45","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/sj.mt.6300020","volume":"15","author":"ID Iankov","year":"2007","unstructured":"Iankov ID, Blechacz B, Liu C, Schmeckpeper JD, Tarara JE, Federspiel MJ et al. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther 2007; 15: 114\u2013122.","journal-title":"Mol Ther"},{"key":"BFcgt201454_CR46","doi-asserted-by":"publisher","first-page":"7246","DOI":"10.1158\/1078-0432.CCR-09-1292","volume":"15","author":"EK Mader","year":"2009","unstructured":"Mader EK, Maeyama Y, Lin Y, Butler GW, Russell HM, Galanis E et al. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res 2009; 15: 7246\u20137255.","journal-title":"Clin Cancer Res"},{"key":"BFcgt201454_CR47","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1182\/blood-2013-09-528851","volume":"123","author":"A Castleton","year":"2014","unstructured":"Castleton A, Dey A, Beaton B, Patel B, Aucher A, Davis DM et al. Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. Blood 2014; 123: 1327\u20131335.","journal-title":"Blood"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cgt201454.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201454","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201454.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T12:23:05Z","timestamp":1647951785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cgt201454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["BFcgt201454"],"URL":"https:\/\/doi.org\/10.1038\/cgt.2014.54","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"23 June 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}